- Report
- November 2021
Global
From €31885EUR$34,500USD£26,879GBP
- Report
- June 2022
- 198 Pages
Global
From €2236EUR$2,419USD£1,885GBP
€3194EUR$3,456USD£2,693GBP
Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery.
Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia.
Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more